FDA Clears Stem Cell Clinical Trial

FDA‘s decision “marks the dawn of a new era in medical therapeutics,” Thomas B. Okarma, president and CEO of Geron, said during a teleconference briefing. GRNOPC1 is intended to “permanently reverse disease pathology, not merely to temporarily relieve symptoms,” he noted.

via FDA Clears Stem Cell Clinical Trial | Chemical & Engineering News: Latest News.

Related articles:

• New Prez, New Era for Stem Cells?